Highlights

  • Healius (ASX:HLS) is reviewing strategic Options for Agilex Biolabs while continuing its broader Business reshaping.
  • The company has focused on cost reductions, Debt management and improving underlying profitability.
  • Pathology operations continue to face wage Inflation and funding pressures.
  • FY26 results and updates on the Agilex process remain key areas for investors to monitor.

Healius (ASX:HLS) has spent the past year repositioning its business towards a more focused pathology model while addressing cost pressures and operational challenges. The company’s review of Agilex Biolabs, its clinical-trials laboratory division, forms part of this broader strategy.

The potential divestment of Agilex highlights the balance Healius faces between simplifying its operations and retaining a division that has delivered higher growth compared with its core pathology business.

What Happened

On 13 May 2026, Healius announced that it had appointed UBS Securities Australia to assess strategic options for Agilex Biolabs, including a potential divestment, after receiving unsolicited interest from external parties.

No transaction has been completed, and Agilex continues operating within the Healius group. The company stated that any potential sale would not affect its core pathology operations.

The review followed an update on full-year guidance and commentary around labour cost pressures affecting the pathology sector.

The potential sale follows previous portfolio changes, including the divestment of Lumus Imaging in 2025. Healius used proceeds from that transaction to reduce debt, refinance facilities and return Capital to shareholders.

The Numbers Investors Need to Know

Agilex Biolabs generated Revenue of $21.8 million in H1'FY26, representing 16% year-on-year growth, with Earnings Before Interest and Tax (EBIT) of $2.7 million and an EBIT Margin of 12.4%.

The core pathology business recorded first-half revenue of $666.3 million, up 3.5%, with EBIT of $5.2 million. However, pathology volumes declined 0.4% over the 10 months to April 2026, while revenue growth moderated to 2.4%.

At group level, H1'FY26 revenue increased 3.8% to $688.1 million, underlying Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) increased 13.1% to $122.2 million, and underlying EBIT moved to a $7.9 million profit compared with a $2.7 million loss in the prior corresponding period.

Healius guided to FY26 underlying EBITDA of $259–264 million and underlying EBIT of $30–35 million.

At 31 December 2025, Healius held $51.6 million of cash against $40 million of drawn debt, resulting in a net cash position of $11.6 million.

Why This Matters

The Agilex review reflects the company’s broader effort to simplify its business structure. Agilex has delivered higher growth compared with the core pathology division, making any potential sale a strategic decision rather than a routine asset disposal.

A divestment could provide additional capital flexibility, although management has not committed to any specific use of potential proceeds.

The company continues to focus on improving pathology returns through cost reductions, operational changes and efficiency initiatives while managing external pressures from wages and Medicare funding conditions.

The Bull Case

The Investment case is based on continued execution of cost reduction initiatives and improved operating performance.

Healius is targeting $15–20 million in annual support cost savings. The company reported $7.3 million of annualised savings in FY25 and a further $10.7 million annualised benefit in H1'FY26.

Approximately 400 full-time-equivalent roles have been removed as part of restructuring initiatives. Labour costs represented 50.7% of revenue in H1'FY26 compared with 51.0% previously.

A potential Agilex transaction could provide additional financial flexibility, although the outcome and terms remain uncertain.

The Risks

Healius (ASX:HLS)’s business faces risks including wage inflation, Medicare funding constraints, softer pathology volumes, execution challenges and uncertainty around the Agilex review outcome.

Pathology labour costs remain under pressure following Fair Work Commission decisions, with Healius expecting a $1.8 million impact in Q4'FY26 and additional increases from July 2026 and January 2027.

The company also faces uncertainty around referral volumes, as lower GP attendance affects pathology demand.

A strategic review does not guarantee a transaction, and any sale of Agilex could reduce exposure to one of the group’s faster-growing divisions.

What Comes Next

The key upcoming event is the FY26 result, where Healius is expected to provide an update on the Agilex review and progress against guidance.

Investors will monitor whether the company advances towards a potential transaction, delivers further cost savings and manages ongoing wage-related pressures.

The company’s ability to maintain profitability improvements while addressing pathology sector challenges will remain central to its outlook.

Bottom Line

Healius (ASX:HLS) is continuing its business reshaping process while balancing portfolio simplification with the need to retain growth opportunities.

The Agilex review represents a potential strategic decision that could provide additional capital flexibility, but the company’s longer-term performance remains closely linked to pathology operations, cost management and funding conditions.

The next phase of the turnaround will depend on execution of efficiency initiatives, management of external cost pressures and clarity around the future structure of the business.